Lantheus Medical Imaging Release: New Study Published in the Journal of Nuclear Cardiology Explores the Utility of SPECT Myocardial Perfusion Imaging with Cardiolite(R) in Patients with New-Onset of Heart Failure

N. BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, announced today new data from a prospective, non-randomized, multi-national study that shows gated single-photon emission computed tomographic (SPECT) myocardial perfusion imaging (MPI) with Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) had a 96 percent negative predictive value for diagnosing extensive coronary artery disease in patients hospitalized with their first episode of heart failure. These study findings were published in the January/February 2009 issue of The Journal of Nuclear Cardiology.

Back to news